




## COVID-19 Vaccine Program

**Four vaccines GEO-CM01-04 designed; animal testing results: H2 '21.**

**Universal Coronavirus vaccine** Focused on providing immunity to SARS-CoV-2 and seasonal coronavirus strains.

**"Single-dose, universal coronavirus vaccine"** for COVID-19, COVID-20, etc.



**Advancing to Clinic** Focused on accelerating development into clinical testing.

**No FDA requirement** for toxicology testing expected.


**Scale up** for Emergency Use Authorization readiness during Phase 1a/1b clinical trial.

## Immuno-oncology Program

### Triple-threat Approach

- 1** Tumor antigen specific immune responses stimulated
- 2** Immune inhibition blocked with checkpoint inhibitors
- 3** Tumor cells killed using an oncolytic virus

### GeoVax Concept for Cancer Immunotherapy



Tumor Regression

**Stimulate** MVA-VLP with tumor antigen to provoke immune system

**Block** Checkpoint inhibitor to reverse immune tolerance

**Kill** Achieve oncolysis using armed vaccinia virus

## GeoVax - A Compelling Investment Opportunity

- Focused on areas of critical medical needs providing significant commercial opportunities;
- Clinical stage and IND-enabling programs successfully advancing;
- Novel, differentiated platform validated across infectious disease vaccines and immuno-oncology;
- New Filings Expands and Strengthens Intellectual Property Portfolio;
- Capital structure and balance sheet supporting advancing programs into milestone clinical development

## Strong IP Protection

**70**  
**Granted**  
or pending patent applications spread over 20 patent families

IR Contact: Tristan Traywick  
CORE IR / 377 Oak Street  
Garden City, NY 11530  
investor@geovax.com